| ²é¿´: 4597 | »Ø¸´: 1 | |||
agathis121½ð³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇóÖúÎÄÏ×µÄCSCD(Öйú¿ÆÑ§ÒýÎÄÊý¾Ý¿â)¼ìË÷£¨ÊÕ¼ºÅ£©¼°¼ìË÷±¨¸æ
|
|
±êÌ⣺½Íĸëõ°°×Sup35NMµÄ¹Ñ¾Û»¯¹ý³ÌÑо¿ ±êÌ⣺Oligomerization of yeast prion Sup35NM ×÷ÕߣºÍõÑÞ¾°, ÎâÆæ À´Ô´ Öйú¿ÆÑ§: ÉúÃü¿ÆÑ§, ³ö°æÄê:2018,48(6):662 ~ 670 |
» ²ÂÄãϲ»¶
AÇøÒ»±¾½»²æ¿ÎÌâ×飬µÍ·Öµ÷¼Á£¬ÕÐÊÕ»úеµç×ÓÐÅϢͨÐŵȽ»²æ·½Ïò
ÒѾÓÐ15È˻ظ´
²ÄÁÏѧ˶318Çóµ÷¼Á
ÒѾÓÐ18È˻ظ´
½Î÷ʦ·¶´óѧÍõÀ¥-¬Õ»ԿÎÌâ×éÕл¯Ñ§·½Ïò˶ʿÑо¿ÉúÁ½Ãû
ÒѾÓÐ3È˻ظ´
ûÉϰ¶µÄ¿´¹ýÀ´
ÒѾÓÐ5È˻ظ´
290Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
²ÄÁÏÓ뻯¹¤£¬291£¬Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
301Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸¶«±±´óѧ080500£¬Ó¢Ò»Êý¶þ343·ÖÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
274»·¾³¹¤³ÌÇóµ÷¼Á
ÒѾÓÐ6È˻ظ´
304Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
nudtscf
ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
- LS-EPI: 12
- Ó¦Öú: 15 (СѧÉú)
- ½ð±Ò: 12422
- É¢½ð: 107
- ºì»¨: 33
- ɳ·¢: 4
- Ìû×Ó: 2127
- ÔÚÏß: 145.9Сʱ
- ³æºÅ: 1534134
- ×¢²á: 2011-12-12
- ÐÔ±ð: GG
- רҵ: ͼÊé¹Ý¡¢Ç鱨ÓëÎÄÏ×ѧÆäËû
¡ï ¡ï ¡ï ¡ï ¡ï
agathis121(Ðľ²_ÒÀÈ»´ú·¢): ½ð±Ò+5, ¸ÐлӦÖú 2019-06-11 08:45:30
agathis121(Ðľ²_ÒÀÈ»´ú·¢): ½ð±Ò+5, ¸ÐлӦÖú 2019-06-11 08:45:30
|
ÎÄÕª ±¾ÎÄÑо¿ÁËÓëÉñ¾ÍËÐÐÐÔ¼²²¡Ïà¹Øµ°°×ÓÐÀàËÆ¾Û¼¯ÐÐΪµÄÄ£Ð͵°°×ÖʽÍĸëõ°°×Sup35NMµÄ´íÎóÕÛµþ¹ý³Ì,ÌØ±ðÊdzõʼµÄ¹Ñ¾Û»¯¹ý³Ì.ΪÁËÑÓ»ººÍ×èÖ¹ëõ°°×Sup35NMÔÚÁ×ËáÑλº³åÒºÖÐ(ÌåÍâÌõ¼þ)µÄ¾Û¼¯ÒÔÀûÑо¿,ÔÚSup35NMµÄN½á¹¹ÓòµÚ31λµã´¦Í»±ä²¢ÐÞÊÎÁËÒ»¸ö¾ÛºÏÎï·Ö×ÓPNIPAM (¼´µ°°×ÖÊ-¸ß·Ö×Ó½áºÏÎïSup35NM-31m-PNIPAM).Áò´ú»ÆËØTÓ«¹â¹âÆ×ʵÑéÏÔʾ,ÐÞÊÎÑÓ»ºÁËSup35NMµÄ¹Ñ¾Û»¯,²¢¸ø³öÁËÑо¿¹Ñ¾Û»¯µÄʱ¼ä´°¿Ú: 25¡æÊ±,ÐÞÊÎǰºó·Ö±ðÊÇ~10ºÍ24 h.¼¤¹â¹âÉ¢ÉäʵÑé½øÒ»²½Ö¤ÊµÁËÐÞÊÎ×è°Sup35NM¹Ñ¾Û»¯¾Û¼¯.ÔËÓÃSmoluchowskiÄ£Ð͹«Ê½,ÄâºÏÁ˼¤¹â¹âÉ¢ÉäʵÑéÊý¾Ý,¶¨Á¿µØ¸ø³ö²¢¶Ô±ÈÁËÐÞÊÎǰºóÁ½¸öÑùÆ·ÔÚ¾Û¼¯³õÆÚ(6 hÄÚ)µÄ¹Ñ¾ÛÌå·Ö²¼.½á¹ûÏÔʾ,ÔÚÒý·¢¾Û¼¯6 hºó,δÐÞÊÎÑùÆ·Öеĵ°°×Öʵ¥Ìå½öÊ£13%,¶øÔÚPNIPAMÐÞÊκóµÄÑùÆ·Öе°°×Öʵ¥ÌåÔòÈÔÕ¼46%.±¾¹¤×÷Ϊ¿É¿Ø¡¢¶¨Á¿Ñо¿ëõ°°×¹Ñ¾Û»¯ÌṩÁËÐÂ˼·. ÆäËûÓïÖÖÎÄÕª We have studied the misfolding process of a neurodegenerative disease-related protein, yeast prion Sup35NM, especially the initial oligomerization prcoess. To slow down the aggregation rate of Sup35NM in phasphate buffer saline in vitro, we conjugated a commercial available maleimide terminated-poly(N-isopropylacrylamide) (PNIPAM) molecule at the specific 31st residue site on Sup35NM by site-directed mutagenesis and thiol-ene click chemistry, which results in a Sup35NM-31m-PNIPAM conjugate. The aggregation process of Sup35NM was hindered after modification by PNIPAM at 25¡æ. The ThT fluorescence assay provided a time window for studying the oligomerization prcoess (or lag phase) of Sup35NM (~10 h) and the Sup35NM-31m-PNIPAM conjugate (~24 h) based on the onset of the fluorescence intensity. Further, the results of LLS confirmed the inhibition effect of PNIPAM modification on the oligomerization of Sup35NM due to its high sensitivity on the small aggregates. Finally, the Smoluchowski coagulation equation was adopted to analyze the data from laser light scattering, which provides us quantitative results on the lag phase kinetics and oligomer distribution of the two samples during the initial 6 h upon aggregation. The results show that there only exsits ~13% monomers in the sample of the Sup35NM at 6 h after initiating the protein association process, while nearly half of the protein chains exsit as monomers for the Sup35NM-31m-PNIPAM conjugate. In summary, the current work provides a controlable and quantative way to study the oligomerization behavior of the amyloidogenic proteins. À´Ô´ Öйú¿ÆÑ§. ÉúÃü¿ÆÑ§ ,2018,48(6):662-670 ¡¾ºËÐĿ⡿ DOI 10.1360/N052018-00022 ¹Ø¼ü´Ê µ°°×ÖÊÕÛµþ ; Éñ¾ÍËÐÐÐÔ¼²²¡ ; Sup35NMëõ°°× ; µ°°×Öʵ͍µã¸ß·Ö×ÓÐÞÊÎ ; ¹Ñ¾Û»¯¹ý³Ì µØÖ· 1. Ïã¸ÛÖÐÎÄ´óѧ»¯Ñ§Ïµ, Ïã¸Û 2. Öйú¿ÆÑ§¼¼Êõ´óѧ»¯Ñ§ÎïÀíϵ, ºÏ·Ê΢³ß¶ÈÎïÖÊ¿ÆÑ§¹ú¼ÒÑо¿ÖÐÐÄ, ºÏ·Ê, 230026 ÓïÖÖ ÖÐÎÄ ISSN 1674-7232 ѧ¿Æ ÉúÎﻯѧ »ù½ð Ïã¸ÛÌØ±ðÐÐÕþÇø×¨Ïî»ù½ð ÎÄÏ×ÊղغŠCSCD:6277296 ¼ìË÷±¨¸æµÃÕÒͼÊé¹Ý×öµÄ |

2Â¥2019-05-23 08:58:01













»Ø¸´´ËÂ¥
10